Class / Patent application number | Description | Number of patent applications / Date published |
514401000 | 2-imidazolines | 75 |
20080319041 | Lofexidine enantiomers for use as a treatment for CNS disease and pathologies and its chiral synthesis - The invention relates to methods for treatment of CNS disease and pathologies using non-racemic mixtures of lofexidine enantiomers. The invention also relates to processes for the manufacture of chirally pure enantiomers of lofexidine. | 12-25-2008 |
20090018180 | 2-IMIDAZOLINES - The present invention relates to compounds of formula I | 01-15-2009 |
20090048323 | SUBSTITUTED IMIDAZOLINE COMPOUNDS - Substituted imidazoline derivatives corresponding to Formula I: | 02-19-2009 |
20090197931 | IMIDAZOLINYLMETHY ARYL SULFONAMIDE - This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I: | 08-06-2009 |
20090197932 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE - This invention relates to an alpha-1A receptor partial agonist, which is represented by Formula I: | 08-06-2009 |
20090197933 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE - This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I: | 08-06-2009 |
20090197934 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE - This invention relates to an alpha-1A receptor partial agonist, which is represented by Formula I: | 08-06-2009 |
20090264489 | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation - Effective methods for treating pain are provided. Through the injection of liquid formulation comprising an active ingredient followed by the administration of drug depot comprising an active ingredient at or near a target site, one can effectively treat pain. This methodology is particularly effective to treat acute radicular pain. | 10-22-2009 |
20090264490 | CLONIDINE FORMULATIONS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 10-22-2009 |
20090264491 | METHODS AND COMPOSITIONS FOR TREATING POST-OPERATIVE PAIN COMPRISING CLONIDINE - The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days. | 10-22-2009 |
20100063123 | EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION - A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a a2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the a2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9. | 03-11-2010 |
20100120881 | CHEMICAL COMPOUNDS - The present invention relates to imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. In particular the present invention relates to imidazolines with alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl or heterocyclyl substituents. | 05-13-2010 |
20100120882 | PHENOXYMETHYL IMIDAZOLINE DERIVATIVES AND THEIR USE AS PESTICIDES - The present invention relates to imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. In particular the present invention relates to imidazolines with alkyl and fluoro substituents. | 05-13-2010 |
20100184817 | METHODS OF TREATING NEUROPATHY - Methods and compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and methods for administering the compositions to treat various neuropathies. | 07-22-2010 |
20100267795 | NITROSUBSTITUTED ARYLOXYALKYLIMIDAZOLINES FOR USE AS PESTICIDES - The present invention relates to imidazoline derivatives and their use as insecticidal and acaricidal agents. The invention also extends to insecticidal and acaricidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect and acarine pests. In particular the present invention relates to phenoxy-imidazoline derivatives wherein the phenoxy moiety is substituted with a nitro group. A method of combating and/or controlling an insect or acarid pest, which comprises applying to said pest, or to the locus of said pest, or to a plant susceptible to attack by said pest, a compound of formula (I): or salt or N-oxide thereof. | 10-21-2010 |
20100280088 | HALOSUBSTITUTED ARYLOXYALKYLIMIDAZOLINES FOR USE AS PESTICIDES - The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. A compound of formula (I) and salts and N-oxides thereof, wherein: R | 11-04-2010 |
20110098331 | HALOALKYLSUBSTITUTED ARYLOXYALKYLIMIDAZOLINES FOR USE AS PESTICIDES - The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, mollus and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. A compound of formula (I): and the salts and N-oxides thereof. | 04-28-2011 |
20110136884 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF - The invention provides methods for treating disorders associated with selective subtype modulation of alpha 2 adrenergic receptors. In particular, the invention provides methods employing well-defined N-[1-(2 and/or 3-substituted-phenyl)-alkyl]-(4,5-dihydro-1H-imidazol-2-yl)-amines and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation, such as ocular disorders, pain and central nervous system (CNS) motor disorders. | 06-09-2011 |
20110160267 | Method of treating diabetic retinopathy - A method for treating diabetic retinopathy involving topically administering to an eye of a patient a pharmacologically effective amount of a compound represented by the following formula [II] or a salt thereof: | 06-30-2011 |
20110160268 | COMPOSITIONS AND METHODS FOR TREATING LUNG DISORDERS - The present invention relates to methods of treating subjects with alveolar capillary membrane injury or methods of preventing alveolar capillary membrane injury in subjects, with the methods comprising administering to the subjects a therapeutically effective amount of ergothioneine and a pharmaceutically acceptable carrier. The invention also relates to methods of screening candidate compounds for their ability to mitigate the effects of alveolar capillary membrane injury. | 06-30-2011 |
20110178147 | COMPOSITIONS AND METHODS FOR CONTROLLING PUPIL DILATION - The disclosure provides a composition for controlling pupil dilation comprising about 0.001% to about 1.0% by weight of an alpha-adrenergic receptor antagonist selected from phentolamine, phentolamine mesylate, or a phentolamine salt; and at least one excipient selected from the group consisting of a buffer, tonicity agent, preservative, antioxidant, surfactant, solubilizer, cosolvent, and a combination thereof. A method of controlling pupil dilation in a subject in need thereof, comprising administering a therapeutically effective amount of the composition is also provided. | 07-21-2011 |
20110184037 | METHODS FOR TREATING AN INTERVERTEBRAL DISC USING LOCAL ANALGESICS - Effective methods of treating back pain from an intervertebral disc are provided. The methods of treatment include administering an immediate release analgesic at or near the intervertebral disc; administering a bulking agent or sealing agent within the intervertebral disc; and administering a sustained release analgesic within the intervertebral disc, wherein the sustained release analgesic releases the analgesic over a period of at least one day. | 07-28-2011 |
20110230535 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE - This invention relates to an alpha-1A receptor partial agonist, which is represented by Formula I: | 09-22-2011 |
20110237639 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE - This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I: | 09-29-2011 |
20110245314 | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation - A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α | 10-06-2011 |
20110288140 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS - The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. Inanother aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity. | 11-24-2011 |
20120029042 | CLONIDINE FOR TREATMENT OF BONE CANCER - The present invention is directed to a method for treating osteolytic bone cancer. The method comprises implanting a drug depot locally at or near the osteolytic bone cancer, wherein the drug depot comprises at least one biodegradable polymer and clonidine in an amount from about 0.1 wt. % to about 30 wt. % of the drug depot. | 02-02-2012 |
20120035235 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS - Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic. | 02-09-2012 |
20120101141 | GEL COMPOSITIONS AND METHODS OF USE - Improved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage. | 04-26-2012 |
20120142747 | COMPOSITIONS AND METHODS FOR DELIVERING CLONIDINE TO A TARGET TISSUE SITE - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release clonidine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days or longer. | 06-07-2012 |
20120149748 | Pharmaceutical Cream Compositions and Methods of Use - The present invention provides pharmaceutical cream compositions comprising oxymetazoline and methods for treating rosacea and other skin disorders as described herein using the above cream compositions. | 06-14-2012 |
20120225918 | Compositions and Methods for Non-Surgical Treatment of Ptosis - Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis. | 09-06-2012 |
20120225919 | Compositions and Methods for Non-Surgical Treatment of Ptosis - Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis. | 09-06-2012 |
20120225920 | Compositions and Methods for Non-Surgical Treatment of Ptosis - Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis. | 09-06-2012 |
20120316213 | COMBINATION OF ALPHA-2 RECEPTOR AGONIST (CLONIDIN) AND ANTI-MUSCARINIC AGENT (OXYBUTYNIN) FOR THE TREATMENT OF SIALORRHOEA - An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium. | 12-13-2012 |
20130023575 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE ALLERGIES - The disclosure provides ophthalmic compositions, systems and methods for the treatment of ocular surface allergies. More particularly the present invention relates to compositions of bromfenac for the treatment of the signs and symptoms of ocular surface allergies due to seasonal allergies. | 01-24-2013 |
20130079379 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE - Embodiments relating to gels comprising imidazoline alpha agonists, such as, without limitation, oxymetazoline or a pharmaceutically acceptable salt thereof, and methods for treating diseases, such as, without limitation, rosacea, including, for example, erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, ocular rosacea or combinations thereof; and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema or redness associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith or combinations thereof using such gels are described herein. | 03-28-2013 |
20130085171 | COMPOUNDED TRANSDERMAL PAIN MANAGEMENT - The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and/or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include a salt load of approximately 30% or greater. The transdermal cream may include a unique base composition such that the transdermal cream may be able to remain stable and avoid degradation for six months or more and capable of effective delivery of active ingredient concentrations exceeding approximately 40% or more of the total formulation weight. The active ingredients may include a nerve depressant, NSAID, muscle relaxant, opiate agonist, local anesthetic, NMDA receptor antagonist, and a tricyclic antidepressant. In one embodiment, the transdermal cream may comprise ketamine HCL, gabapentin, clonidine HCL and baclofen. The transdermal cream may deliver an enhanced topical delivery flux of ketamine via a single transdermal application. | 04-04-2013 |
20130123320 | TOPICAL COMPOSITION FOR PAIN RELIEF - Described is a topically applied composition relief of pain. Also described are methods of preparing the composition and methods of using the composition to relieve pain. | 05-16-2013 |
20130150418 | APPARATUS AND METHOD FOR THE TREATMENT OF ABNORMAL UTERINE BLEEDING - Method and apparatus are disclosed for applying a therapeutic amount of a non-systemic vasoconstrictor inside the uterus to control abnormal uterine bleeding. The abnormal bleeding can be due to excessive menstrual blood flow, bleeding from a surgical procedure, postpartum bleeding or any other acute or chronic condition. The vasoconstrictor includes topical agents such as an alpha-adrenergic agonist, for example oxymetazoline. The delivery system can include a catheter having means for retaining position of a distal portion within the uterus. A proximal portion can extend outside of the body for coupling to a vasoconstrictor source, or alternatively, the proximal portion can terminate within the vaginal canal and include a docking port for coupling to a source of vasoconstrictor that is inserted therein. In other embodiments, an applicator is disclosed that is positioned in fluid communication with the lumen of the cervix and allows application of a vasoconstrictor therein. | 06-13-2013 |
20140094498 | METHODS AND COMPOSITIONS FOR TREATING POST-OPERATIVE PAIN COMPRISING CLONIDINE - The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days. | 04-03-2014 |
20140121257 | ALPHA-1-ADRENERGIC RECEPTOR AGONIST THERAPY - Presented herein inter alia are novel methods of treating heart and brain diseases. | 05-01-2014 |
20140206737 | Application of Clonidine Hydrochloride as an Information Intervention Agent and an Information Intervention Product and the Method of Making the Same - This invention relates to a new application of compound Clonidine Hydrochloride in a use of preparation of information intervention agent, a new preparation method of information intervention agent, and a product. The Clonidine Hydrochloride interacts with the human information receptor, therefore realizing the intervention through the Clonidine Hydrochloride information physical method, and treatment was not a chemical treatment. This invention comprises: putting the compound Clonidine Hydrochloride information package filler ( | 07-24-2014 |
20140213625 | Methods and Compositions for Treating Foot or Hand Pain - The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand. | 07-31-2014 |
20140221445 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF - The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water. | 08-07-2014 |
20140221446 | METHODS AND COMPOSITIONS FOR DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE TO IMPROVE VISUAL PERFORMANCE - The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours. | 08-07-2014 |
20140221447 | FORMULATION FOR PREVENTING OR REDUCING BLEEDING AT A SURGICAL SITE - An implantable drug depot useful for preventing, reducing or treating bleeding at a surgical site beneath the skin in a patient is provided. The implantable drug depot comprises a therapeutically effective amount of clonidine or a pharmaceutically acceptable salt thereof, and at least one biodegradable polymer. The drug depot is capable of releasing clonidine or a pharmaceutically acceptable salt thereof over a period of at least three days. | 08-07-2014 |
20140235687 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM - Methods for treating cognitive dysfunction by modulating brain energy metabolism using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed. | 08-21-2014 |
20140309269 | DIAGNOSIS AND TREATMENT OF P.R.I.C.E. SYNDROME - A method for treating a patient having P.R.I.C.E. Syndrome is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form. | 10-16-2014 |
20140309270 | DIAGNOSIS AND TREATMENT OF A FORM OF AUTISTIC SPECTRUM DISORDER - A method for treating a patient having P.R.I.C.E. Syndrome is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form, optionally in combination with a therapeutically effective amount of inositol and/or NAC. | 10-16-2014 |
20140309271 | TREATMENT OF AUTISTIC SPECTRUM DISORDER - A method for treating a patient having ASD is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form in combination with a therapeutically effective amount of inositol. | 10-16-2014 |
20140329874 | ALPHA ADRENERGIC AGONISTS FOR THE TREATMENT OF TISSUE TRAUMA - The present invention provides a method of treating tissue trauma (such as damage from radiation (such as solar and ultraviolet radiation), wounds, bruising, burns, blisters, excoriations, incisions, excisions, and ulcers) in a subject, comprising topically administering to the tissue area of the subject affected by said trauma a composition comprising a therapeutically effective amount of at least one alpha adrenergic agonist (such as oxymetazoline hydrochloride). The present invention also provides a method for alleviating the pain or discomfort associated with aesthetic or plastic surgery or cosmetology procedures in a subject comprising administering said alpha adrenergic agonist. | 11-06-2014 |
20140364475 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYELID SWELLING - The invention features topical formulations comprising an osmotically active agent and/or a vasoconsgtrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof. | 12-11-2014 |
20150057325 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST - The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC. | 02-26-2015 |
20150119437 | Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism - Methods for treating cognitive dysfunction by modulating brain energy metabolism using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed. | 04-30-2015 |
20150126572 | INOSITOL-CONTAINING COMESTIBLE UNITS AND METHODS OF TREATING AUTISTIC SPECTRUM DISORDER USING THE SAME - A method for treating a patient having ASD is disclosed. The method includes administering to the patient a plurality of comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol. The method may further include administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form. | 05-07-2015 |
20150148396 | CLONIDINE FORMULATIONS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 05-28-2015 |
20150148397 | CLONIDINE FORMULATIONS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 05-28-2015 |
20150148398 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS - The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity. | 05-28-2015 |
20150314040 | STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES - The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. | 11-05-2015 |
20150359781 | STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES - The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient. | 12-17-2015 |
20150374665 | CLONIDINE FORMULATION IN A POLYORTHOESTER CARRIER - Effective treatments of acute pain for extended periods of time are provided. The treatments include the administration of one or more drug depots at or near a target site wherein the drug depots include an effective amount of clonidine formulated within a polyorthoester. By administration of one or more drug depots at or near the target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days. | 12-31-2015 |
20160038465 | Compositions and Methods for Non-Surgical Treatment of Ptosis - Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis. | 02-11-2016 |
20160051515 | METHODS AND COMPOSITIONS FOR DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE TO IMPROVE VISUAL PERFORMANCE - The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours. | 02-25-2016 |
20160095963 | METHODS AND COMPOSITIONS FOR TREATING POST-OPERATIVE PAIN COMPRISING CLONIDINE - The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days. | 04-07-2016 |
20160152560 | Compounds for the treatment of hypertension and hypertensive end stage renal disease | 06-02-2016 |
20160166696 | Stable Anti-inflammatory Solutions for Injection | 06-16-2016 |
20160184269 | DENTAL ANESTHETIC COMPRISING TETRACAINE AND A VASOCONSTRICTOR FOR INTRANASAL ADMINISTRATION - The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations. | 06-30-2016 |
514402000 | Additional hetero ring | 7 |
20080221191 | Cationic substituted benzofurans as antimicrobial agents - A method of treating a | 09-11-2008 |
20080262067 | PHARMACEUTICAL COMPOSITION BASED ON IDAZOXAN, SALTS, HYDRATES OR POLYMORPHS THEREOF - A pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs. | 10-23-2008 |
20100331384 | GUANIDINE BASED COMPOUNDS - The adrenergic receptors or adrenoceptors are a family of G-protein coupled receptors split into α and β subclasses. The adrenoceptors have important roles in regulating a myriad of physiological conditions and their malfunction has been implicated in the pathophysiology of a number of diseases. Disclosed herein are a series of novel guanidine and 2-aminoimidazoline compounds which are ligands of the alpha2-adrenoceptor (α2-ARs) subclass of adrenergic receptors. The invention also provides for pharmaceutical compositions comprising the novel compounds. The compounds are suitable for use in the manufacture of medicaments for the treatment of α2-ARs associated disorders, such as depression, schizophrenia, glaucoma and analgesia. | 12-30-2010 |
20150299172 | 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury - The present invention relates to compounds of formula I: | 10-22-2015 |
20160152572 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS | 06-02-2016 |
20160166546 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | 06-16-2016 |
20180022707 | THERAPEUTIC COMPOUNDS AND USES THEREOF | 01-25-2018 |